<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03130452</url>
  </required_header>
  <id_info>
    <org_study_id>2016-09-0025</org_study_id>
    <nct_id>NCT03130452</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Eradication Study</brief_title>
  <official_title>Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inje University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the efficacy and compliance of tailored therapy
      which using the polymerase chain reaction for point mutation of clarithromycin, compared to
      concomitant therapy, in patients without history of H. pylori eradication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose of Study&gt;

        1. To evaluate the efficacy of tailored therapy compared to concomitant therapy.

        2. Difference in eradication rate according to the frequency of 23S ribosomal RNA point
           mutation in clarithromycin.

        3. To evaluate the compliance of tailored therapy compared to concomitant.

        4. To analysis of factors which influence to the eradication rate.

      Patients&gt;

      ; Target disease

        -  peptic ulcers(gastric ulcer, duodenal ulcer),

        -  gastric MALToma,

        -  Endoscopic therapy state of early gastric cancer or gastric adenoma,

        -  Patients who require H. pylori testing by clinical judgment, such as chronic gastritis.

      Method&gt;

      Patients with H. pylori infection who have been screened for a 23S ribosomal RNA point
      mutation (A2142G, A2143G point mutation) and randomized to a concomitant treatment group and
      a tailored treatment group. In concomitant treatment group, lansoprazole 30 mg, amoxicillin
      1.0 g, metronidazole 500 mg and clarithromycin 500 mg were administered twice a day for 2
      weeks, regardless of 23S ribosomal RNA point mutation. In tailored treatment group, In the
      case of 23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and
      clarithromycin 500 mg were administered twice a day for 2 weeks. In tailored treatment group,
      In point mutation positive cases, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500
      mg For 2 weeks. For each treatment group, at least 4 weeks after completion of drug
      administration, confirm the sterilization and confirm the compliance and adverse effects of
      the drug.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of success rate of H. pylori eradication between tailored therapy and concomitant therapy.</measure>
    <time_frame>At 4 weeks after the completion of drug administration, the urea breath test is performed to check for eradication, Before the urea breath test, the proton pump inhibitor or H2 blocker should be discontinued for 2 weeks.</time_frame>
    <description>Comparison of percentage of people who succeeded in H. pylori eradication among all participants in each treatment group (tailored therapy vs concomitant therapy)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in eradication rate according to the frequency of 23S ribosomal RNA point mutation in clarithromycin</measure>
    <time_frame>Before the treatment, 23S ribosomal RNA point mutation is confirmed and at least 4 weeks after the end of treatment, urea breath test is performed to check whether or not eradication is completed.</time_frame>
    <description>Identify the effect of 23S ribosomal RNA point mutation on the eradication rate regardless of the administration drug.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of remaining medicines of tailored therapy compared to concomitant therapy</measure>
    <time_frame>At 4 weeks after the completion of drug administration, when the patient visited for the urea breath test, check the number of remaining medicines.</time_frame>
    <description>After taking the treatment drug, take out all remaining medicine in the outpatient clinic room, check the number of remaining medicines, and judge compliance.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>concomitant group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lansoprazole 30 mg tablet, amoxicillin 1.0 g tablet, metronidazole 500 mg tablet and clarithromycin 500 mg tablet by mouth every 12 hours for 2 weeks, regardless of 23S ribosomal RNA point mutation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tailored treatment group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>23S ribosomal RNA point mutation negative, lansoprazole 30 mg, amoxicillin 1.0 g, and clarithromycin 500 mg were administered twice a day for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tailored treatment group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>23S ribosomal RNA point mutation positive, lansoprazole 30 mg, amoxicillin 1.0 g and metronidazole 500 mg For 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 30mg</intervention_name>
    <description>lansoprazole 30 mg tablet</description>
    <arm_group_label>concomitant group</arm_group_label>
    <arm_group_label>tailored treatment group I</arm_group_label>
    <arm_group_label>tailored treatment group II</arm_group_label>
    <other_name>langton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin 1.0g Tab</intervention_name>
    <description>Amoxicillin 1.0g tablet</description>
    <arm_group_label>concomitant group</arm_group_label>
    <arm_group_label>tailored treatment group I</arm_group_label>
    <other_name>amoxiclav</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin 500mg</intervention_name>
    <description>Clarithromycin 500mg tablet</description>
    <arm_group_label>concomitant group</arm_group_label>
    <arm_group_label>tailored treatment group I</arm_group_label>
    <arm_group_label>tailored treatment group II</arm_group_label>
    <other_name>clavacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 500 mg</intervention_name>
    <description>Metronidazole 500 mg tablet</description>
    <arm_group_label>concomitant group</arm_group_label>
    <arm_group_label>tailored treatment group II</arm_group_label>
    <other_name>lysinyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  H. pylori infection diagnosed patient, between 18 years old and 80 years old

          -  No history of H. pylori eradication therapy

          -  No antibiotic use for more than 3 days within 1 month of treatment

        Exclusion Criteria:

          -  History of taking antibiotics for more than 3 days in the last 1 month

          -  History of subtotal or partial gastrectomy

          -  Patients with other systemic disorders such as severe liver function, kidney function,
             cardiopulmonary function abnormality

          -  Pregnant and lactating women

          -  Disagree with the survey or do not respond to the questionnaire

          -  Contraindications for each medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Hyun Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University Busan Paik hosipital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje University Busan Paik hosipital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inje University</investigator_affiliation>
    <investigator_full_name>Kim Ji Hyun</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to make individual patient data available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

